Eli Lilly and Co. entered a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis shareholders could receive as much as $1.925 billion in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain development and sales milestones. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II A...